Andrea Casadei-Gardini1, Giulia Rovesti2, Vincenzo Dadduzio3, Caterina Vivaldi4, Eleonora Lai5, Sara Lonardi3, Lorenzo Fornaro6, Andrea Pretta5, Vittorina Zagonel3, Laura Bernardini4, Giorgio Astara5, Francesco E D'Amico7, Gianluca Masi4, Margherita Rimini2, Mario Scartozzi5, Stefano Cascinu8. 1. Department of Medical Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, 20019, Milan, Italy. Electronic address: casadeigardini@gmail.com. 2. Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121, Modena, Italy. 3. Medical Oncology Unit 1, Veneto Institute of Oncology IRCCS, Padua, Italy. 4. Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via savi 10, 56126, Pisa PI, Italy. 5. Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy. 6. U.O. Oncologia Medica 2 Universitaria, Azienda Ospedaliero-Universitaria Pisana, via Roma 67, 56126 Pisa, Italy. 7. Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy. 8. Department of Medical Oncology, Università Vita-Salute, San Raffaele Hospital IRCCS, 20019, Milan, Italy.
Abstract
BACKGROUND AND AIM: The aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib. METHODS: 304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan-Meier method and compared with the log-rank test. RESULTS: The concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02). CONCLUSION: Globally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib.
BACKGROUND AND AIM: The aim of our retrospective study is to evaluate the prognostic significance of aspirin in patients with advanced HCC treated with sorafenib. METHODS: 304 patients with HCC,consecutively treated with sorafenib from May 2007 to September 2018, were included in the clinical study. Of Them 93 patients token aspirin. Progression-free survival (PFS)and overall survival (OS)were estimated with the Kaplan-Meier method and compared with the log-rank test. RESULTS: The concomitant use of sorafenib and aspirin was associated with a median OS of 18.3 months compared to 8.8 months of patients who did not receive aspirin (HR 0.57; P < 0.0001). The concomitant use of sorafenib and aspirin was associated with a median PFS of 7.3 months compared to 3.0 months of patients who did not receive aspirin (HR 0.61; P = 0.0003). In the multivariate analysis, the use of aspirin maintained an independent prognostic value for OS(HR 0.61; P = 0.0013). In second line the concomitant use of regorafenib and aspirin was associated with a median OS of 16.9 months compared to 8.0 months of patients who did not receive aspirin (HR 0.30; P = 0.02). CONCLUSION: Globally, our data seem to suggest that aspirin use may improve the clinical outcome of patients with advanced hepatocellular carcinoma receiving sorafenib and regorafenib.
Authors: Dario Spanu; Andrea Pretta; Eleonora Lai; Mara Persano; Clelia Donisi; Stefano Mariani; Marco Dubois; Marco Migliari; Giorgio Saba; Pina Ziranu; Valeria Pusceddu; Marco Puzzoni; Giorgio Astara; Mario Scartozzi Journal: World J Hepatol Date: 2022-07-27